
    
      This is a randomized, double-blind, parallel-group, multicenter study to evaluate the
      efficacy and safety of HX575 epoetin alfa vs. US-licensed epoetin alfa (Epogen®/Procrit®) in
      the treatment of anemia associated with chronic kidney disease (CKD).
    
  